BCHE and Alzheimer disease: In a longitudinal study of prodromal AD, 39% of APOE4 and BCHE-K carriers aged less than 75 years progressed to AD over 3–4 years, while 18% of patients aged 75 years or more progressed to AD over 3–4 years [33].